RESUMEN
Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset psychosis, participants aged 15-40â¯years with recent onset schizophrenia-spectrum (nâ¯=â¯46) or bipolar (nâ¯=â¯4) disorders and current psychotic symptoms were treated for 16â¯weeks with risperidone and randomly-assigned omega-3 (EPA 740â¯mg and DHA 400â¯mg daily) or matching placebo. The primary outcome measure was the Brief Psychiatric Rating Scale (BPRS) total score. Mean lifetime antipsychotic exposure was 18.1â¯days. Length of time in treatment, risperidone dose and number of omega-3/placebo capsules taken did not differ between conditions. Longitudinal analysis of the total BPRS score revealed a trend level (pâ¯=â¯0.0826) treatment effect favoring omega-3 treatment. Lorazepam was an allowed concomitant medication. Among the subgroup (Nâ¯=â¯23) who did not receive lorazepam, the treatment effect on BPRS total scores favoring omega-3 was significant (pâ¯=â¯0.0406) and factor scores analyses revealed a substantial decrease in depression-anxiety with omega-3 but no change with placebo (treatment-by-time interaction, pâ¯=â¯0.0184). Motor side effects did not differ between conditions. Analysis of Systematic Assessment for Treatment Emergent Events assessments revealed fewer adverse events overall with omega-3 compared with placebo with the largest differences between conditions (all favoring omega-3) on confusion, anxiety, depression, irritability, and tiredness/fatigue. These results suggest that omega-3 adjuvant treatment is a potential option for depression and anxiety symptoms of people with recent onset psychosis. Further research is needed to confirm this potential. Clinical trial registration: NCT01786239.
Asunto(s)
Antipsicóticos/farmacología , Ansiedad/tratamiento farmacológico , Trastorno Bipolar/tratamiento farmacológico , Depresión/tratamiento farmacológico , Ácidos Grasos Omega-3/farmacología , Trastornos Psicóticos/tratamiento farmacológico , Risperidona/farmacología , Esquizofrenia/tratamiento farmacológico , Adolescente , Adulto , Antipsicóticos/administración & dosificación , Ansiedad/etiología , Trastorno Bipolar/complicaciones , Escalas de Valoración Psiquiátrica Breve , Depresión/etiología , Quimioterapia Combinada , Ácidos Grasos Omega-3/administración & dosificación , Femenino , Humanos , Masculino , Evaluación de Resultado en la Atención de Salud , Trastornos Psicóticos/complicaciones , Risperidona/administración & dosificación , Esquizofrenia/complicaciones , Adulto JovenRESUMEN
While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20â¯years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject. Hence, very little is known about how chronic treatment with drugs that affect multiple receptors like APDs influence the response to a potential pro-cognitive agent. Therefore, the purpose of this study was to evaluate the α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonist, tropisetron in rats chronically treated with APDs with distinct pharmacological profiles. Rats were treated orally with either risperidone (2.5â¯mg/kg/day) or quetiapine (25.0â¯mg/kg/day) for 30 or 90â¯days and then an acute injection of vehicle or tropisetron (3.0â¯mg/kg) was administered before training in a novel object recognition (NOR) task. After a 48 h delay (when recollection of the familiar object was impaired in vehicle-treated animals) neither 30 nor 90â¯days of risperidone or quetiapine treatment improved NOR performance. In contrast, tropisetron markedly improved NOR performance in rats treated with either APD for 30 or 90â¯days. These animal data reinforce the argument that two commonly prescribed APDs are not pro-cognitive agents and that α7 nAChR ligands like tropisetron have potential as adjunctive treatments in schizophrenia.
Asunto(s)
Antipsicóticos/farmacología , Fumarato de Quetiapina/farmacología , Reconocimiento en Psicología/efectos de los fármacos , Risperidona/farmacología , Tropisetrón/farmacología , Receptor Nicotínico de Acetilcolina alfa 7/agonistas , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Relación Dosis-Respuesta a Droga , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Agonismo Parcial de Drogas , Masculino , Fumarato de Quetiapina/administración & dosificación , Fumarato de Quetiapina/sangre , Ratas Wistar , Risperidona/administración & dosificación , Risperidona/sangre , Tropisetrón/administración & dosificación , Tropisetrón/sangreRESUMEN
BACKGROUND: The chronic use of antipsychotics has been associated with impaired bone mineralization, partially mediated by hyperprolactinemia. We examined if calcium and vitamin D supplementation promote bone mineral accrual in boys with risperidone-induced hyperprolactinemia. METHODS: Between February 2009 and November 2013, medically healthy, 5- to 17-year-old boys were enrolled in a 36-week double-blind, placebo-controlled study, examining the skeletal effects of supplementation with 1250 mg calcium carbonate and 400 IU of vitamin D3 in risperidone-induced hyperprolactinemia. Anthropometric, dietary, physical activity, and psychiatric assessments were conducted at baseline and week 18 and 36. Plasma prolactin and vitamin D concentrations were measured at baseline and week 36. Total body less head bone mineral content (BMC) and radius trabecular bone mineral density (BMD) were measured at baseline, week 18, and week 36, using dual-energy X-ray absorptiometry and peripheral quantitative computed tomography, respectively. Linear mixed-effects regression analysis examined the longitudinal effect of treatment on skeletal outcomes. RESULTS: Forty-seven boys (mean age: 11.0 ± 2.6 years) were randomized and 38 completed the study. At study entry, the average dietary calcium intake was below the recommended limit, but the average vitamin D concentration was normal. Calcium and vitamin D supplementation failed to significantly increase BMC or trabecular BMD. It also failed to affect several other skeletal and anthropometric outcomes, including plasma vitamin D concentration. CONCLUSIONS: In this 9-month long pilot study, supplementation with a modest dose of calcium and vitamin D did not increase bone mass accrual in risperidone-treated boys with hyperprolactinemia. Alternative approaches should be investigated to optimize bone health in this population to prevent future morbidity and premature mortality. ClinicalTrials.gov Identifier: NCT00799383.
Asunto(s)
Carbonato de Calcio/administración & dosificación , Colecalciferol/administración & dosificación , Hiperprolactinemia/tratamiento farmacológico , Risperidona/efectos adversos , Absorciometría de Fotón , Adolescente , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Densidad Ósea/efectos de los fármacos , Calcio de la Dieta/administración & dosificación , Niño , Preescolar , Suplementos Dietéticos , Método Doble Ciego , Humanos , Hiperprolactinemia/inducido químicamente , Masculino , Proyectos Piloto , Análisis de Regresión , Risperidona/administración & dosificaciónRESUMEN
PURPOSE: To assess whether a "drugome-wide" screen with case-crossover design is a feasible approach for identifying candidate drugs and drug-drug interactions. METHODS: All community-dwelling residents of Finland who received a clinically verified Alzheimer disease diagnosis in 2005 to 2011 and experienced incident hip fracture (HF) afterwards (N = 4851). Three scenarios were used to test the sensitivity of this approach (1) hazard period 0 to 30 and control period 31 to 61 days before HF, (2) hazard period 0 to 30 and control period 336 to 366 days before HF, and (3) hazard period 0 to 14 and control period 16 to 30 days before HF. RESULTS: Nine, 44, and 5 drugs were associated with increased HF risk and 8, 23, and 4 with decreased risk in scenarios 1, 2, and 3, respectively. Six drugs were identified with scenario 1 only and 54 and 1 with scenarios 2 and 3, respectively. Only six drugs (metoprolol, simvastatin, trimethoprim, codeine combinations, fentanyl, and paracetamol) were associated with HF in all scenarios, four with 1 and 2 (cefalexin, buprenorphine, olanzapine, and memantine), and one with 1 and 3 (enalapril) or 2 and 3 (ciprofloxacin). The direction of associations was the same in all/both scenarios. The interaction results were equally versatile, with hydroxocobalamin*oxazepam being the only interaction observed in all scenarios. CONCLUSIONS: Case-crossover analysis is a potential approach for identifying candidate drugs and drug-drug interactions associated with adverse events as it implicitly controls for fixed confounders. The results are highly dependent on applied hazard and control periods, but the choice of periods can help in targeting the analyses to different phases of drug use.
Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/epidemiología , Interacciones Farmacológicas/fisiología , Fracturas de Cadera/inducido químicamente , Fracturas de Cadera/epidemiología , Acetaminofén/administración & dosificación , Acetaminofén/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/diagnóstico , Codeína/administración & dosificación , Codeína/efectos adversos , Estudios Cruzados , Evaluación Preclínica de Medicamentos/métodos , Femenino , Finlandia/epidemiología , Fracturas de Cadera/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Risperidona/administración & dosificación , Risperidona/efectos adversosRESUMEN
This work aimed to deepen the lately acquired knowledge about parenteral nanoemulsions as carriers for brain delivery of risperidone, a poorly water-soluble antipsychotic drug, through establishing the prospective relationship between their physicochemical, pharmacokinetic, biodistribution, and behavioral performances. For this purpose, two optimized risperidone-loaded nanoemulsions, stabilized by lecithin or lecithin/polysorbate 80 mixture, and costabilized by sodium oleate, were produced by high-pressure homogenization. The characterization revealed the favorable droplet size, narrow size distribution, high surface charge, with proven stability to autoclaving and long-term stability for at least one year at 25±2°C. Pharmacokinetic and tissue distribution results demonstrated improved plasma, liver, and brain pharmacokinetic parameters, resulting in 1.2-1.5-fold increased relative bioavailability, 1.1-1.8-fold decreased liver distribution, and about 1.3-fold improved brain uptake of risperidone active moiety following intraperitoneal administration of nanoemulsions relative to solution in rats. In behavioral study, investigated nanoemulsions showed pronounced reduction in basal and, more pertinently, amphetamine-induced locomotor activity in rats, with an early onset of antipsychotic action, and this effect lasted at least 90min after drug injection. Together, these findings corroborate the applicability of parenteral nanoemulsions as carriers for enhanced brain delivery of risperidone, further suggesting their promise in acute psychosis treatment or other emergency situations.
Asunto(s)
Antipsicóticos/administración & dosificación , Nanoestructuras/administración & dosificación , Risperidona/administración & dosificación , Animales , Antipsicóticos/sangre , Antipsicóticos/química , Antipsicóticos/farmacocinética , Disponibilidad Biológica , Proteínas Sanguíneas/metabolismo , Encéfalo/metabolismo , Sistemas de Liberación de Medicamentos , Emulsiones , Lecitinas/química , Hígado/metabolismo , Locomoción/efectos de los fármacos , Masculino , Nanoestructuras/química , Ácido Oléico/química , Polisorbatos/química , Trastornos Psicóticos/tratamiento farmacológico , Trastornos Psicóticos/metabolismo , Ratas Wistar , Risperidona/sangre , Risperidona/química , Risperidona/farmacocinética , Distribución TisularRESUMEN
BACKGROUND: Antipsychotics are essential for the treatment of schizophrenia. However, due to side effects, both continuity of treatment and patients' general health can be jeopardized. Some of these drugs, especially clozapine, have a class of side effects attributed to their antimuscarinic properties, such as dysmotility, a condition in which muscles of the digestive system become impaired. Dysmotility may also alter the speed, strength or coordination of the digestive organs, causing distention, disturbing gastrointestinal transit, leading to symptoms such as bloating, nausea, vomiting, and even malnutrition. In this study, our aim was to develop an in vivo assay capable of identifying and studying the antimuscarinic effects of antipsychotics in a zebrafish model. METHODS: We performed video recordings of in vivo 5-day postfertilization (dpf) zebrafish larvae gastrointestinal tracts and analyzed the frequency of spontaneous and regular cycles of contractions of the gut. KEY RESULTS: The assay was first validated with treatment with atropine. We showed that this antimuscarinic drug reduces peristaltic cycles. Subsequently, the larvae were treated with the antipsychotics haloperidol, risperidone, and clozapine. Neither haloperidol nor risperidone reduced gut motility, but clozapine significantly reduced the frequency of cycles of contractions (P<.0001), which confirms the existing clinical data. CONCLUSIONS & INFERENCES: We conclude that this zebrafish assay efficiently identifies anticholinergic side effects of antipsychotics, and can thus be a quick and useful way to screen for this property in new drugs.
Asunto(s)
Antipsicóticos/administración & dosificación , Evaluación Preclínica de Medicamentos/métodos , Motilidad Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/efectos de los fármacos , Animales , Atropina/administración & dosificación , Clozapina/administración & dosificación , Haloperidol/administración & dosificación , Larva , Antagonistas Muscarínicos/administración & dosificación , Risperidona/administración & dosificación , Pez CebraRESUMEN
En el área sanitaria de Santiago de Compostela, el subgrupo terapéutico "otros antipsicóticos" era el quinto en mayor gasto extrahospitalario en el año 2013, correspondiendo más de la mitad a la risperidona y paliperidona parenterales de acción prolongada. La implantación de un programa de seguimiento farmacoterapéutico basado en la gestión por procesos y en la coordinación de actuaciones entre profesionales sanitarios de ambos niveles asistenciales supuso, en 12 meses un ahorro para la organización de 636.391,01 €, para el paciente de 16.767,36 € en aportaciones y 9.008 desplazamientos a la oficina de farmacia. Este trabajo muestra la eficiencia del programa facilitado por tratarse de un área de gestión integrada y utilizar la historia clínica única y prescripción electrónica, elementos que posibilitan la implantación futura de programas similares. Los nuevos registros y actuaciones asistenciales permitirán una evaluación fiable de su efectividad en relación a la adherencia terapéutica, recaídas y hospitalizaciones
In the healthcare area of Santiago de Compostela (Spain), the therapeutic subgroup "other antipsychotics" represented the fifth largest outpatient expenditure in 2013. More than half of this expenditure corresponded to long-acting parenteral forms of paliperidone and risperidone. Over a 12-month period, the implementation of a pharmaceutical care program based on process management and coordination of actions between health professionals in both levels of care represented savings of € 636,391.01 for the organization and a direct saving of € 16,767.36 and 9,008 trips to the pharmacy for patients. This study shows the efficiency of the program, which was facilitated by its situation in an area of integrated management and the use the unified medical records and electronic prescription, elements that will enable the future implementation of similar programmes. The new registries and healthcare interventions will allow reliable evaluation of their effectiveness in terms of treatment adherence, relapses and hospitalizations
Asunto(s)
Humanos , Antipsicóticos/uso terapéutico , Farmacovigilancia , Trastornos Psicóticos/tratamiento farmacológico , Risperidona/administración & dosificación , Administración del Tratamiento Farmacológico/organización & administración , Evaluación de Programas y Proyectos de Salud/estadística & datos numéricos , Infusiones Parenterales , Preparaciones de Acción Retardada/administración & dosificación , Prestación Integrada de Atención de Salud/organización & administraciónRESUMEN
In the healthcare area of Santiago de Compostela (Spain), the therapeutic subgroup "other antipsychotics" represented the fifth largest outpatient expenditure in 2013. More than half of this expenditure corresponded to long-acting parenteral forms of paliperidone and risperidone. Over a 12-month period, the implementation of a pharmaceutical care program based on process management and coordination of actions between health professionals in both levels of care represented savings of 636,391.01 for the organization and a direct saving of 16,767.36 and 9,008 trips to the pharmacy for patients. This study shows the efficiency of the program, which was facilitated by its situation in an area of integrated management and the use the unified medical records and electronic prescription, elements that will enable the future implementation of similar programmes. The new registries and healthcare interventions will allow reliable evaluation of their effectiveness in terms of treatment adherence, relapses and hospitalisations.
Asunto(s)
Antipsicóticos/uso terapéutico , Prestación Integrada de Atención de Salud/organización & administración , Servicios Farmacéuticos/organización & administración , Antipsicóticos/administración & dosificación , Antipsicóticos/economía , Antipsicóticos/farmacocinética , Áreas de Influencia de Salud , Ahorro de Costo , Análisis Costo-Beneficio , Preparaciones de Acción Retardada , Eficiencia Organizacional , Prescripción Electrónica , Humanos , Inyecciones , Palmitato de Paliperidona/administración & dosificación , Palmitato de Paliperidona/economía , Palmitato de Paliperidona/farmacocinética , Palmitato de Paliperidona/uso terapéutico , Pautas de la Práctica en Medicina , Honorarios por Prescripción de Medicamentos , Risperidona/administración & dosificación , Risperidona/economía , Risperidona/farmacocinética , Risperidona/uso terapéutico , EspañaRESUMEN
This paper describes design and evaluation of parenteral lecithin-based nanoemulsions intended for brain delivery of risperidone, a poorly water-soluble psychopharmacological drug. The nanoemulsions were prepared through cold/hot high pressure homogenization and characterized regarding droplet size, polydispersity, surface charge, morphology, drug-vehicle interactions, and physical stability. To estimate the simultaneous influence of nanoemulsion formulation and preparation parameters--co-emulsifier type, aqueous phase type, homogenization temperature--on the critical quality attributes of developed nanoemulsions, a general factorial experimental design was applied. From the established design space and stability data, promising risperidone-loaded nanoemulsions (mean size about 160 nm, size distribution <0.15, zeta potential around -50 mV), containing sodium oleate in the aqueous phase and polysorbate 80, poloxamer 188 or Solutol(®) HS15 as co-emulsifier, were produced by hot homogenization and their ability to improve risperidone delivery to the brain was assessed in rats. Pharmacokinetic study demonstrated erratic brain profiles of risperidone following intraperitoneal administration in selected nanoemulsions, most probably due to their different droplet surface properties (different composition of the stabilizing layer). Namely, polysorbate 80-costabilized nanoemulsion showed increased (1.4-7.4-fold higher) risperidone brain availability compared to other nanoemulsions and drug solution, suggesting this nanoemulsion as a promising carrier worth exploring further for brain targeting.
Asunto(s)
Encéfalo/metabolismo , Emulsiones/química , Nanopartículas/química , Risperidona/administración & dosificación , Risperidona/farmacocinética , Animales , Química Farmacéutica , Sistemas de Liberación de Medicamentos , Estabilidad de Medicamentos , Emulsionantes , Lecitinas/química , Masculino , Tamaño de la Partícula , Poloxámero/química , Polietilenglicoles/química , Polisorbatos/química , Ratas , Ratas Wistar , Solubilidad , Ácidos Esteáricos/química , Tecnología FarmacéuticaRESUMEN
We present a case of a patient who was diagnosed with Hashimoto's encephalopathy based on the presence of subacute behavioural changes, negative work up for infection and immunological serology except for high serum titres of thyroid autoantibodies. Thyroid function tests (TFTs) and MRI of the brain were normal. EEG showed low amplitude, slow waves and θ waves at both frontal areas. His condition improved dramatically after treated with high-dose glucocorticoid. After 2 years of a relapsing-remitting course, a new episode occurred. There was an abrupt change of TFTs within 5 days: free thyroxine (fT4) from 1.52 to 1.53 ng/mL, free triiodothyronine (fT3) from 3.25 to >30 pg/mL and thyroid-stimulating hormone (TSH) from 5.08 to 0.78 mIU/L. On the following day found fT4 2.58, fT3 14.67 and TSH 0.042. The patient was diagnosed with Hashitoxicosis. High-dose glucocorticoid and ß-blockers were initiated. The symptoms gradually improved and TFTs normalised within 2 weeks.
Asunto(s)
Antiinflamatorios/administración & dosificación , Antipsicóticos/administración & dosificación , Autoanticuerpos/efectos de los fármacos , Encefalopatías/tratamiento farmacológico , Enfermedad de Hashimoto/tratamiento farmacológico , Prednisolona/administración & dosificación , Risperidona/administración & dosificación , Adulto , Autoanticuerpos/sangre , Encefalopatías/fisiopatología , Encefalitis , Enfermedad de Hashimoto/fisiopatología , Humanos , Masculino , Recurrencia , Pruebas de Función de la Tiroides , Resultado del TratamientoRESUMEN
Second generation antipsychotic drugs (SGAs) such as risperidone are increasingly prescribed (mostly for off-label use) to children and adolescents for treating various mental disorders. SGAs cause serious weight gain/obesity and other metabolic side-effects. This study aimed to establish an animal model of risperidone-induced weight gain in female juvenile rats, and to investigate the effects of risperidone on the expression of hypothalamic histaminergic H1 receptors (H1R) and neuropeptides, and their association with weight gain. Female Sprague Dawley rats were treated orally with risperidone (0.3mg/kg, 3 times/day) or vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period corresponding to the childhood-adolescent period in humans). In the female juvenile rats, risperidone treatment increased food intake and body weight gain, which started to appear after 12 days' treatment. Risperidone also significantly decreased the locomotor activity of the female rats. Consistently, risperidone significantly elevated mRNA expression of hypothalamic H1R, neuropeptide Y (NPY), and agouti-related peptide (AgRP) compared to controls, and H1R and NPY levels were correlated with risperidone enhanced weight gain and food intake in the female juvenile rats. However, risperidone did not affect hypothalamic proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) mRNA expression. Therefore, these results suggested that risperidone elevated appetite and body weight gain in juveniles via regulation of the hypothalamic H1R, NPY and AgRP pathways, as well as by reducing activity.
Asunto(s)
Antipsicóticos/efectos adversos , Hipotálamo/efectos de los fármacos , Neuropéptido Y/metabolismo , Receptores Histamínicos H1/metabolismo , Risperidona/efectos adversos , Aumento de Peso/efectos de los fármacos , Proteína Relacionada con Agouti/metabolismo , Animales , Antipsicóticos/administración & dosificación , Ingestión de Alimentos/efectos de los fármacos , Femenino , Hipotálamo/metabolismo , Actividad Motora/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas Sprague-Dawley , Risperidona/administración & dosificaciónRESUMEN
INTRODUCTION: The combination of antipsychotic drugs is a therapeutic resource in clinical practice. This study aimed to evaluate the efficacy and security of adding amisulpride in patients who at least partially responded to risperidone. METHODS: A 3-month, open, observational study was undertaken to evaluate the effectiveness of adding amisulpride in subjects who scored at least 25 on the brief psychiatric rating scale (BPRS) after risperidone monotherapy. Patients were evaluated with BPRS, the Clinical Global Impressions Severity of Illness scale (CGI-S) and the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU) at baseline, 1 and 3 months. RESULTS: Coadjuvant treatment with amisulpride achieves a statistically significant improvement in mental status over a period of 3 months when measured with BPRS, CGI and UKU scales. The response rate was 70 (45%) in the oral risperidone and 74 (28%) in the parenteral risperidone groups. DISCUSSION: The addition of amisulpride could lead to an improvement in schizophrenia symptoms in patients that do not, or only partially, respond to risperidone. Further research is required into alternative therapies for poor responders.
Asunto(s)
Risperidona/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Sulpirida/análogos & derivados , Administración Oral , Adulto , Anciano , Amisulprida , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Antipsicóticos/uso terapéutico , Quimioterapia Combinada/efectos adversos , Femenino , Humanos , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica , Risperidona/administración & dosificación , Sulpirida/uso terapéutico , Adulto JovenRESUMEN
OBJECTIVE: Atypical antipsychotics, increasingly used in children and adolescents, modulate brain dopamine. Iron plays a critical role in dopaminergic signaling. Therefore, we explored whether body iron status is related to psychiatric symptom severity, treatment response, and tolerability following extended antipsychotic therapy. METHODS: Between November 2005 and August 2009, medically healthy 7-17-year-old risperidone-treated participants enrolled in a cross-sectional study examining the long-term safety of this antipsychotic. Anthropometric measurements were obtained. Psychiatric symptom severity and dietary intake were assessed. Serum ferritin, transferrin receptor, and prolactin concentrations were measured. Linear multivariable regression analysis tested the association among body iron, symptom severity, the dose of risperidone and psychostimulants, and serum prolactin concentration. RESULTS: The sample consisted of 115 patients (87% males) with a mean (±SD) age of 11.6 (±2.8) years. The majority had externalizing disorders, and they had taken risperidone for 2.4 (±1.7) years. Body iron was low, with 45% having iron depletion and 14% having iron deficiency. Iron status was inversely associated with weight gain during risperidone treatment and with interleukin-6. Body iron was neither associated with psychiatric symptom severity nor with the daily dose of risperidone and psychostimulants. It was, however, inversely associated with prolactin concentration, which was nearly 50% higher in the iron-deficient group. CONCLUSIONS: Iron depletion and deficiency are prevalent in children and adolescents chronically treated with risperidone. Iron deficiency accentuates the antipsychotic-induced elevation in prolactin. Future studies should confirm this finding and investigate the potential benefit of iron supplementation in antipsychotic-treated patients.
Asunto(s)
Antipsicóticos/uso terapéutico , Deficiencias de Hierro , Trastornos Mentales/tratamiento farmacológico , Risperidona/uso terapéutico , Adolescente , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Estimulantes del Sistema Nervioso Central/administración & dosificación , Estimulantes del Sistema Nervioso Central/uso terapéutico , Niño , Estudios Transversales , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Interleucina-6/metabolismo , Modelos Lineales , Masculino , Trastornos Mentales/fisiopatología , Análisis Multivariante , Prevalencia , Prolactina/sangre , Risperidona/administración & dosificación , Risperidona/efectos adversos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Aumento de Peso/efectos de los fármacosRESUMEN
INTRODUCTION: Paliperidone is a second-generation (atypical) antipsychotic approved for the treatment of schizophrenia in adults and in adolescents aged 12 - 17 years. It is also approved for the treatment of adults with schizoaffective disorder, both as a monotherapy and as adjunctive therapy to mood stabilizers and/or antidepressants. Paliperidone is the active metabolite of risperidone. AREAS COVERED: The purpose of this review is to describe the pharmacokinetic profile of paliperidone and its clinical implications in the treatment of schizophrenia and schizoaffective disorder. Background information is also provided regarding chemistry, pharmacodynamics, clinical efficacy and safety/tolerability data. EXPERT OPINION: The recommended dose of paliperidone extended-release (ER) in adults is 6 mg/day and no initial dose titration is required. Higher doses may provide additional benefit as well as dose-related increases in some adverse reactions. The maximum recommended dose is 12 mg/day. Peak plasma concentrations are reached approximately 24 h after dosing. Pharmacokinetics are dose-proportional. Terminal half-life is approximately 23 h. Renal excretion is the major route of elimination. Although paliperidone is the active metabolite of risperidone, paliperidone's route of metabolism and elimination is quite different from that for risperidone and paliperidone ER may be preferred over risperidone when liver disease, drug-drug interactions or other alterations in metabolism render the appropriate dosing of risperidone difficult to determine for an individual patient. The use of paliperidone ER will need to be considered within the context of its cost and availability as risperidone is now a generic product.
Asunto(s)
Antipsicóticos/administración & dosificación , Antipsicóticos/química , Antipsicóticos/farmacocinética , Isoxazoles/administración & dosificación , Isoxazoles/química , Isoxazoles/farmacocinética , Pirimidinas/administración & dosificación , Pirimidinas/química , Pirimidinas/farmacocinética , Administración Oral , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Interacciones Farmacológicas , Semivida , Humanos , Palmitato de Paliperidona , Ensayos Clínicos Controlados Aleatorios como Asunto , Risperidona/administración & dosificación , Risperidona/química , Risperidona/farmacocinética , Esquizofrenia/tratamiento farmacológicoRESUMEN
Ginkgo biloba has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of Ginkgo biloba extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of autism. Forty-seven outpatients with a DSM-IV-TR diagnosis of autism ages between 4 and 12 years were assigned to this double blinded clinical trial and were randomly divided into two groups. One group received risperidone plus Ginko T.D and the other received risperidone plus placebo. The dose of risperidone was 1-3 mg/day and the dose of Ginko T.D. was 80 mg/day for patients under 30 kg and 120 mg/day for patients above 30 kg. Patients were assessed using Aberrant Behavior Checklist-Community (ABC-C) rating scale and the side effect check list every 2 weeks until the endpoint. None of the 5 subscales of ABC-C rating scale showed significant differences between the two groups. Incidents of side effects were not significantly different between the two groups. Adding Ginkgo biloba to risperidone did not affect the treatment outcome of ADs. Nevertheless, further observations are needed to confirm this result.
Asunto(s)
Conducta Infantil/efectos de los fármacos , Trastornos Generalizados del Desarrollo Infantil/tratamiento farmacológico , Ginkgo biloba , Fitoterapia , Risperidona , Administración Oral , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Niño , Trastornos Generalizados del Desarrollo Infantil/diagnóstico , Preescolar , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Método Doble Ciego , Quimioterapia Combinada , Femenino , Humanos , Irán , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/efectos adversos , Escalas de Valoración Psiquiátrica , Risperidona/administración & dosificación , Risperidona/efectos adversos , Resultado del TratamientoRESUMEN
Second generation antipsychotics (SGAs) have been linked to metabolic and bone disorders in clinical studies, but the mechanisms of these side effects remain unclear. Additionally, no studies have examined whether SGAs cause bone loss in mice. Using in vivo and in vitro modeling we examined the effects of risperidone, the most commonly prescribed SGA, on bone in C57BL6/J (B6) mice. Mice were treated with risperidone orally by food supplementation at a dose of 1.25 mg/kg daily for 5 and 8 weeks, starting at 3.5 weeks of age. Risperidone reduced trabecular BV/TV, trabecular number and percent cortical area. Trabecular histomorphometry demonstrated increased resorption parameters, with no change in osteoblast number or function. Risperidone also altered adipose tissue distribution such that white adipose tissue mass was reduced and liver had significantly higher lipid infiltration. Next, in order to tightly control risperidone exposure, we administered risperidone by chronic subcutaneous infusion with osmotic minipumps (0.5 mg/kg daily for 4 weeks) in 7 week old female B6 mice. Similar trabecular and cortical bone differences were observed compared to the orally treated groups (reduced trabecular BV/TV, and connectivity density, and reduced percent cortical area) with no change in body mass, percent body fat, glucose tolerance or insulin sensitivity. Unlike in orally treated mice, risperidone infusion reduced bone formation parameters (serum P1NP, MAR and BFR/BV). Resorption parameters were elevated, but this increase did not reach statistical significance. To determine if risperidone could directly affect bone cells, primary bone marrow cells were cultured with osteoclast or osteoblast differentiation media. Risperidone was added to culture medium in clinically relevant doses of 0, 2.5 or 25 ng/ml. The number of osteoclasts was significantly increased by addition in vitro of risperidone while osteoblast differentiation was not altered. These studies indicate that risperidone treatment can have negative skeletal consequences by direct activation of osteoclast activity and by indirect non-cell autonomous mechanisms. Our findings further support the tenet that the negative side effects of SGAs on bone mass should be considered when weighing potential risks and benefits, especially in children and adolescents who have not yet reached peak bone mass.
Asunto(s)
Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Resorción Ósea/inducido químicamente , Risperidona/administración & dosificación , Risperidona/efectos adversos , Aumento de Peso/efectos de los fármacos , Adiposidad/efectos de los fármacos , Administración Oral , Animales , Densidad Ósea/efectos de los fármacos , Resorción Ósea/diagnóstico por imagen , Resorción Ósea/patología , Diferenciación Celular/efectos de los fármacos , Femenino , Fémur/diagnóstico por imagen , Fémur/efectos de los fármacos , Infusiones Subcutáneas , Masculino , Ratones , Ratones Endogámicos C57BL , Osteoclastos/citología , Osteoclastos/efectos de los fármacos , Tibia/diagnóstico por imagen , Tibia/efectos de los fármacos , Microtomografía por Rayos XRESUMEN
Multiple drug administration is an important aspect of clinical practice particularly in specific physiological situation such as in neonates, elderly or pregnancy, since in all such situations, possibility of unwanted effects increases due to altered body physiology. In present study, the teratogenic effects of multiple drug administration risperidone, meclizine/pyridoxine and hydralazine have been compared with the teratogenic effects of individual drugs in pregnant mice. Moreover the role of folic acid and α-tocopherol if any had also been investigated in reducing the teratogenic effects of these drugs in combinations.
Asunto(s)
Anomalías Inducidas por Medicamentos/prevención & control , Antieméticos/toxicidad , Antihipertensivos/toxicidad , Evaluación Preclínica de Medicamentos/estadística & datos numéricos , Piridoxina/uso terapéutico , Risperidona/toxicidad , alfa-Tocoferol/uso terapéutico , Animales , Antieméticos/administración & dosificación , Antihipertensivos/administración & dosificación , Evaluación Preclínica de Medicamentos/métodos , Interacciones Farmacológicas , Femenino , Peso Fetal/efectos de los fármacos , Hidralazina/administración & dosificación , Hidralazina/toxicidad , Meclizina/administración & dosificación , Meclizina/toxicidad , Ratones , Risperidona/administración & dosificación , MortinatoRESUMEN
OBJECTIVE To identify whether sarsasapogenin, a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge, would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia. METHODS The trial was a double-blind, placebo-controlled, parallel-group design. The eligible patients were randomized into 2 treatment groups: sarsasapogenin group (sarsasapogenin plus risperidone for 8 weeks, n = 41) and placebo group (risperidone only for 8 weeks, n = 39). At the baseline, as well as at weeks 2, 4 and 8 of treatment, the therapeutic response was measured by using scales including Positive and Negative Symptoms Scale (PANSS), Wechsler Memory Scale (WMS), modified Chinese Wechsler Adult Intelligence Scale (mWAIS), Clinical Global Impression (CGI) and Brief Psychiatry Rating Scale (BPRS). The study period for each subject was 8 weeks and duration of overall trial was 2 years. RESULTS Patients treated with sarsasapogenin plus risperidone demonstrated no statistically significant differences in changes in PANSS, WMS or mWAIS score at the end-point of the trial compared with patients treated with placebo plus risperidone. The incidence of treatment-emergent adverse events in patients treated with sarsasapogenin was not different from that observed in placebo group. CONCLUSION Sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia. Sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia.
Asunto(s)
Antipsicóticos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Risperidona/uso terapéutico , Esquizofrenia/tratamiento farmacológico , Espirostanos/uso terapéutico , Adolescente , Adulto , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Método Doble Ciego , Quimioterapia Combinada , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Risperidona/administración & dosificación , Risperidona/efectos adversos , Esquizofrenia/diagnóstico , Espirostanos/administración & dosificación , Espirostanos/efectos adversos , Escalas de Wechsler/estadística & datos numéricosRESUMEN
Antagonism of prepulse inhibition (PPI) deficits produced by psychotomimetic drugs has been widely used as an effective tool for the study of the mechanisms of antipsychotic action and identifying potential antipsychotic drugs. Many studies have relied on the acute effect of a single administration of antipsychotics, whereas patients with schizophrenia are treated chronically with antipsychotic drugs. The clinical relevance of acute antipsychotic effect in this model is still an open question. In this study, we investigated the time course of repeated antipsychotic treatment on persistent PPI deficit induced by repeated phencyclidine (PCP) treatment. After a baseline test with saline, male Sprague-Dawley rats were repeatedly injected with either vehicle, haloperidol (0.05mg/kg), clozapine (5.0 or 10.0mg/kg), olanzapine (2.0mg/kg), risperidone (1.0mg/kg) or quetiapine (10mg/kg), followed by PCP (1.5mg/kg, sc) and tested for PPI once daily for 6 consecutive days. A single injection of PCP disrupted PPI and this effect was maintained with repeated PCP injections throughout the testing period. Acute clozapine, but not other antipsychotic drugs, attenuated acute PCP-induced PPI disruption at both tested doses. With repeated treatment, clozapine and quetiapine maintained their attenuation, while risperidone enhanced its effect with a significant reduction of PCP-induced disruption toward the end of treatment period. In contrast, repeated haloperidol and olanzapine treatments were ineffective. The PPI effects of these drugs were more conspicuous at a higher prepulse level (e.g. 82dB) and were dissociable from their effects on startle response and general activity. Overall, the repeated PCP-PPI model appears to be a useful model for the study of the time-dependent antipsychotic effect, and may help identify potential treatments that have a quicker onset of action than current antipsychotics.
Asunto(s)
Antipsicóticos/administración & dosificación , Fenciclidina/administración & dosificación , Fenciclidina/toxicidad , Reflejo de Sobresalto/efectos de los fármacos , Estimulación Acústica , Animales , Clozapina/administración & dosificación , Dibenzotiazepinas/administración & dosificación , Interacciones Farmacológicas , Alucinógenos/administración & dosificación , Alucinógenos/toxicidad , Haloperidol/administración & dosificación , Humanos , Masculino , Modelos Animales , Actividad Motora/efectos de los fármacos , Fumarato de Quetiapina , Ratas , Ratas Sprague-Dawley , Reflejo de Sobresalto/fisiología , Risperidona/administración & dosificaciónRESUMEN
OBJECTIVE: Atypical antipsychotic drugs are prescribed to young children for a number of symptoms, some with no Food and Drug Administration approval for children. Effects on growth of children have received little experimental study. We assessed the effects of two atypicals, risperidone and quetiapine, on growth, prolactin, and thyroid hormones of young pigtail macaques (macaca nemestrina), modeling potential effects on 4-8-year-old children. METHODS: Subjects were studied blindly after random assignment to risperidone (N = 10), quetiapine (N = 10), or placebo (N = 20). Four phases were studied: (1) predrug, 9-12 months of age; (2) low dose (risperidone 0.025 mg/kg, quetiapine 2 mg/kg), 13-16 months; (3) high dose (risperidone 0.05 mg/kg, quetiapine 4 mg/kg), 17-20 months; (4) postdrug, 21-24 months. Body weight was measured daily, skeletal dimension monthly, and bone mineralization and hormones bimonthly. RESULTS: Our primary result showed that, compared with placebo, neither drug had detrimental effects on body weight, skeletal dimensions, or thyroid hormones. However, in a transient effect, bone density was lower following low-dose risperidone than either quetiapine or placebo. In both drug phases, risperidone prolactin was higher than the other groups, which did not differ. The higher prolactin of the risperidone group may partially explain the bone density effect. CONCLUSION: This 16-month study of young, developing pigtail macaques given risperidone at doses from 0.025 to 0.05 mg/kg or quetiapine at doses from 2 to 4 mg/kg suggests that these drugs are safe for normal body weight and skeletal growth in young pigtail macaques given an adequate diet, although these drugs are known to cause significant weight gain and other metabolic changes in some children, adolescents, and adult humans. In addition, the results, although transient in our study, also suggest that research in children on bone mineralization effects of risperidone, and possibly other antipsychotic drugs, may be warranted.